Amgen’s $13.4 billion Otezla purchase shows, once more, the direct financial value of IP in the life sciences space
The Californian company cites US patent protection until 2028 as a key driver of the psoriasis drug acquisition, but antitrust concerns remain
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.